The Expression Level of Mir-210 and ZEB1 Gene in CRC Patients
Abstract
Abstract
Background: Colorectal cancer is the fourth leading cause of cancer deaths around the world. This type of cancer, like other cancers, is caused by the influence of environmental and genetic factors. several miRNAs and genes are involved in the initiation and development of colorectal cancer which among them can point to Mir-210 and ZEB1 gene. Recently molecular studies have been conducted on early diagnosis of colorectal cancer. In this study, expression levels of Mir-210 and ZEB1 gene were reported in CRC patients.
Methods: The expression levels of Mir-210 and ZEB1 were checked by Real Time-PCR method in 60 CRC tissues and 60 adjacent normal tissues after RNA extraction and cDNA synthesis. The comparative threshold cycle (2-△△CT) method and T-test was used to compared expression in tumor and controls group.
Results: This study for Mir-210 reported that 75% of tumor samples have increased of expression levels comparison with normal samples (P=0.001) and 60% of tumor samples showed an increase in expression level for ZEB1 gene (P=0.007). Finally, there is a significant difference between the increase of the Mir-210 expression level and stage of cancer (P>0.05).
Keyword: Colorectal cancer, Mir-210, ZEB1, Real Time-PCR method.
Keywords
Full Text:
PDFReferences
Dolatkhah, Roya; Somi, Mohammad Hossein; Bonyadi, Mortaza Jabbarpour; Asvadi Kermani, Iraj; Farassati, Faris; Dastgiri, Saeed (2015): Colorectal cancer in Iran: molecular epidemiology and screening strategies. In Journal of cancer epidemiology 2015.
Duraes, Ronilson Oliveira; Reis, Rui M. V.; Guimaraes, Denise P.; Berardinelli, Gustavo N.; Oliveira, Marco A.; Neto, Cristovam S. (2018): Abstract A69: Epidemiologic, clinical-pathologic, and therapeutic characterization and its correlation with ethnic ancestry in patients with colorectal cancer of the Barretos Cancer Hospital: AACR.
Hasuwa, Hidetoshi; Ueda, Jun; Ikawa, Masahito; Okabe, Masaru (2013): miR-200b and miR-429 function in mouse ovulation and are essential for female fertility. In Science 341 (6141), pp. 71–73.
Lehmann, Waltraut; Mossmann, Dirk; Kleemann, Julia; Mock, Kerstin; Meisinger, Chris; Brummer, Tilman et al. (2016): ZEB1 turns into a transcriptional activator by interacting with YAP1 in aggressive cancer types. In Nature communications 7, p. 10498.
Luo, Jingqin; Giannakis, Marios; Colditz, Graham; Wang, Jean; Chapman, William; Toriola, Adetunji T. et al. (2018): Comparative genomic analysis of young-onset and late-onset colorectal cancer: AACR.
Park, Sun-Mi; Gaur, Arti B.; Lengyel, Ernst; Peter, Marcus E. (2008): The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. In Genes & development 22 (7), pp. 894–907.
Puissegur, M. P.; Mazure, N. M.; Bertero, T.; Pradelli, L.; Grosso, S.; Robbe-Sermesant, K. et al. (2011): miR-210 is overexpressed in late stages of lung cancer and mediates mitochondrial alterations associated with modulation of HIF-1 activity. In Cell death and differentiation 18 (3), p. 465.
Wang, Zhanpeng; Li, Zhuonan; Ye, Yanshuo; Xie, Lijuan; Li, Wei (2016): Oxidative stress and liver cancer: etiology and therapeutic targets. In Oxidative medicine and cellular longevity 2016.
Yang, Xiaoming; Shi, Lei; Yi, Chengzhi; Yang, Yang; Chang, Liansheng; Song, Dongkui (2017): MiR-210-3p inhibits the tumor growth and metastasis of bladder cancer via targeting fibroblast growth factor receptor-like 1. In American journal of cancer research 7 (8), p. 1738.
Ye, Feng; Chen, Mingliang; Wang, Jian; Zhao, Yuanpeng; Cheng, Jin; Zhao, Jiqing et al. (2019): Downregulation of miR-210 promotes sulfur mustard-induced skin wound healing. In International Journal Of Clinical And Experimental Medicine 12 (5), pp. 5279–5287.
Zhang, Peijing; Sun, Yutong; Ma, Li (2015): ZEB1: at the crossroads of epithelial-mesenchymal transition, metastasis and therapy resistance. In Cell cycle 14 (4), pp. 481–487.
DOI: http://dx.doi.org/10.52155/ijpsat.v17.1.1399
Refbacks
- There are currently no refbacks.
Copyright (c) 2019 Maryam Khanbabakhani
This work is licensed under a Creative Commons Attribution 4.0 International License.